 | Up a level |
Ferrari, S; Adachi, J D; Lippuner, Kurt; Zapalowski, C; Miller, P D; Reginster, J-Y; Törring, O; Kendler, D L; Daizadeh, N S; Wang, A; O'Malley, C D; Wagman, R B; Libanati, C; Lewiecki, E M (2015). Further reductions in nonvertebral fracture rate with long-term denosumab treatment in the FREEDOM open-label extension and influence of hip bone mineral density after 3 years. Osteoporosis international, 26(12), pp. 2763-2771. Springer 10.1007/s00198-015-3179-x
Papapoulos, S; Lippuner, Kurt; Roux, C; Lin, C J F; Kendler, D L; Lewiecki, E M; Brandi, M L; Czerwiński, E; Franek, E; Lakatos, P; Mautalen, C; Minisola, S; Reginster, J Y; Jensen, S; Daizadeh, N S; Wang, A; Gavin, M; Libanati, C; Wagman, R B and Bone, H G (2015). The effect of 8 or 5 years of denosumab treatment in postmenopausal women with osteoporosis: results from the FREEDOM Extension study. Osteoporosis international, 26(12), pp. 2773-2783. Springer 10.1007/s00198-015-3234-7
